Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
Market
0.0%
Details
- Resolved Date
- 11/10/25
- Study Completion
- 1/22/26
- Company
- InflaRx GmbH
- Ticker
- IFRX
- Type
- Trial Status
- Terminated
- Trial Size
- 73
- Volume
- $0
- NCT
- NCT06555328
- Drug Description
- The study duration for an individual subject includes screening (14 days), the treatment period (28 days) and the observational follow-up period of 28 days, in total 70 days ± 6 days. All subjects will receive IMP for 28 days followed by one End of Study (EOS) visit, 4 weeks after EOT visit.
Resolution Evidence
- Outcome
- YES
- Status
- Resolved
- Settlement Date
- 4/1/26 UTC
- Executive Summary
Sponsor publicly reported positive topline Phase 2a data for INF904 in HS and CSU and described the trial as successful, with encouraging clinical activity and no safety signals of concern. ClinicalTrials.gov matches NCT06555328 as the exact Phase 2a basket study in these indications.
Sources
Sponsorinflarx.de11/10/25
11-2025-InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurativa (HS) and Chronic Spontaneous Urticaria (CSU)
InflaRx announced positive topline Phase 2a data; the release says INF904 showed strong efficacy potential with no safety signals of concern, and management called the Phase 2a trial a success.
View source
ClinicalTrialsclinicaltrials.gov
Study Details | NCT06555328 | Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
ClinicalTrials.gov identifies NCT06555328 as the exact Phase 2a open-label basket study of INF904 in moderate to severe CSU or hidradenitis suppurativa.
View source
Activity Feed
No activity entries match the current filters for this market.
Model Positions
